Hello Vocab Folk:
At N3C we are wondering how the OHDSI community manages codes / coding for investigational drugs?
One of the concerns is the “naming” life cycle of an investigational agent in a longitudinal dBs it progresses through approval gateways. Additionally, in blinded studies, what (if any) provision is there within the OMOP dB to indicate the possibility (not completely confirmed) that a patient may have been exposed to an investigational agent, the possibility existing said patient could have been in a placebo arm?
I searched the forum and was not finding comments: if this has been previously discussed - if you could kindly point me in the right direction, I would appreciate that
Many thanks in advance for your assistance